Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the 99mTc(CO)3+ core

Bombesin is a neuropeptide widely studied due to its ability to target various types of cancers. Technetium-99m on the other hand is ideal for diagnostic tumor targeting. The aim of the present study is the investigation of the coupling of the ligand (S)-(2-(2′-pyridyl)ethyl)-d,l-cysteine with the BN-peptide Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met(CONH₂) through the spacer aminohexanoic acidand the labeling of the resulting derivative MBN with the synthon [M(CO)₃(H₂O)₃]⁺ (M = ^99mTc, Re). The peptide was synthesized according to the SPPS method, purified and characterized by ESI-MS. The new ^99mTc-labeled biomolecule was stable in vitro, showed high affinity for the human GRP receptor expressed in PC3 cells and the rate of internalization was found to be time-dependent tissue distribution of the radiopeptide was evaluated in normal mice and in prostate cancer experimental models and significant radioactivity uptake was observed in the pancreas of normal mice as well as in PC3 tumors. Dynamic studies of the radiopeptide showed satisfactory tumor images.     

Synthesis, characterization and X-ray crystal structure of [Re(L4)(CO)3]Br · 2CH3OH (L4 = N,N-bis[(2-diphenylphosphino)ethyl]methoxyethylamine): A model compound for novel cationic Tc(I)-tricarbonyl radiotracers useful for heart imaging

This report describes synthesis and evaluation of cationic complexes, [^99mTc(CO)₃(L)]⁺ (L = N-methoxyethyl-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (L1), N-[(15-crown-5)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (L2) and N-[(18-crown-6)-2-yl]-N,N-bis[2-(bis(3-ethoxypropyl)phosphino)ethyl]amine (L3)) as potential radiotracers for heart imaging. Preliminary results from biodistribution studies in female adult BALB-c mice indicated that the cationic ^99mTc(I)-tricarbonyl complex, [^99mTc(CO)₃(L2)]⁺, has a significant localization in the heart at 60 min post-injection. To understand the coordination chemistry of these bisphosphine ligands with the ^99mTc(I)-tricarbonyl core, we prepared [Re(CO)₃(L4)]Br (L4: N,N-bis[(2-diphenylphosphino)ethyl]methoxyethylamine) as a model compound. [Re(CO)₃(L4)]Br has been characterized by elemental analysis, IR, ESI-MS, NMR (¹H, ¹³C, ¹H-¹H COSY, and ¹H-¹³C HMQC) methods, and X-ray crystallography. In solid state, [Re(CO)₃(L4)]⁺ has a distorted octahedron coordination geometry with PNP occupying one facial plane. The chelator backbone adopts a “chair” conformation with phosphine-P atoms at equatorial positions and the amine-N at the apical site. In solution, [Re(CO)₃(L4)]⁺ is able to maintain its cationic nature with no dissociation of carbonyl ligands or any of the three PNP donors.     

Technetium-binding in labelled HYNIC-peptide conjugates: Role of coordinating amino acids

Electrospray mass spectrometry (ESMS) of certain peptides labelled with ^99mTc via hydrazinonicotinamide (HYNIC) with tricine as co-ligand shows one Tc-bound tricine, whereas typically two are observed. We speculated that this was due to coordination of a neighbouring histidine (His) or glutamate (Glu). To investigate this possibility, several short peptides incorporating lysine (HYNIC), with and without His and Glu at different positions in the sequence, were radiolabelled with ^99mTc, using tricine, ethylenediaminediacetic acid (EDDA) and nicotinic acid as co-ligands. The products were examined by HPLC-ESMS, cysteine challenge and bovine serum albumin (BSA) challenge. Peptides with His nearby on either side of lysine (HYNIC) contained only one tricine and showed markedly enhanced structural homogeneity and stability to cysteine challenge and BSA binding, except those with His located at the N-terminus. Peptides without His, or with neighbouring N-terminal His, contained two tricines and were less stable to cysteine challenge and BSA binding. Glu participated in Tc-binding but did not enhance stability. We conclude that neighbouring His or Glu side chains coordinate to Tc and this could alter peptide or protein conformation. Inclusion of His in a neighbouring position to lysine (HYNIC) enhances stability, improves homogeneity and reduces the demand of the metal center for binding to additional co-ligands.     

Syntheses and structural characterization of rhenium-bis-hydrazinopyrimidine core complexes with thiolate and Schiff base coligands

The reaction of perrhenate with 2-hydrazinopyrimidine in MeOH–HCl yields [ReCl₃(η¹-NNC₄H₃N₂H)(η²-HNNC₄H₃N₂)] (1). The analogous reaction with Na₂MoO₄ yields [MoCl₃(η¹-NNC₄H₃N₂H)(η²-HNNHC₄H₃N₂)] (1a). The reaction of 1 with pyrimidine-2-thiol and triethylamine produces [Re(η¹-C₄H₃N₂S)(η²-C₄H₃N₂S)(η¹-NNC₄H₃N₂)(η²-HNNC₄H₃N₂)] (2), while reaction of 1 with the Schiff base HSC₆H₄N=C(H)C₆H₄OH provides [Re(η³-SC₆H₄N=C(H)C₆H₄O)(η¹-NNC₄H₃N₂)(η²-HNNC₄H₃N₂)]·0.6CH₂Cl₂ (3·0.6CH₂Cl₂). The analogous hydrazinopyridine complex of the Schiff base, [Re(η³-SC₆H₄N=C(H)C₆H₄O)(η¹-NNC₅H₄N)(η²-HNNC₅H₄N)] (4), was also synthesized by reacting [ReCl₃(η¹-NNC₅H₄NH)(η²-HNNC₅H₄N)] with HSC₆H₄N=C(H)C₆H₄OH. The crystal structures of 1–4 have been determined.     

Radiation dose and risks to fetus from nuclear medicine procedures

This article discusses issues regarding administration of radiopharmaceuticals to pregnant women. Standardized dose estimates and possible biological effects on the unborn child are presented. Current and future mathematical models (phantoms) are discussed. Standardized dose estimates for pregnant women at several stages of gestation based on the current generation of phantoms are given. Issues related to administration of radioiodines, particularly ¹³¹I-NaI, are presented. Iodine concentrates in the fetal thyroid and therefore can give very high doses, even resulting in complete destruction of the fetal thyroid. Strategies for preventing unwanted administrations of radiopharmaceuticals to these patients, and for strategies for mitigating radiation doses, should an unwanted administration occur, are discussed.     

<Superscript>153</Superscript>Sm and <Superscript>166</Superscript>Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms

A set of tetraaza macrocycles containing pyridine and methylcarboxylate (ac₃py14) or methylphosphonate (MeP₂py14 and P₃py14) pendant arms were prepared and their stability constants with La³⁺, Sm³⁺, Gd³⁺ and Ho³⁺ determined by potentiometry at 25 °C and 0.10 M ionic strength in NMe₄NO₃. The metal:ligand ratio for ¹⁵³Sm and ¹⁶⁶Ho and for ac₃py14, MeP₂py14 and P₃py14, as well as the pH of the reaction mixtures, were optimized to achieve a chelation efficiency higher than 98%. These radiocomplexes are hydrophilic and have a significant plasmatic protein binding. In vitro stability was studied in physiological solutions and in human serum. All complexes are stable in saline and PBS, but 20% of radiochemical impurities were detected after 24 h of incubation in serum. Biodistribution studies in mice indicated a slow rate of clearance from blood and muscle, a high and rapid liver uptake and a very slow rate of total radioactivity excretion. Some bone uptake was observed for complexes with MeP₂py14 and P₃py14, which was enhanced with time and the number of methylphosphonate groups. This biological profile supports the in vitro instability found in serum and is consistent with the thermodynamic stability constants found for these complexes.     

Synthesis,quality control and determination of metallic impurities in 18F-fludeoxyglucose production process

AimThe aim of this study was to synthesize ¹⁸FDG in some consecutive runs and check the quality of manufactured radiopharmaceuticals and to determine the distribution of metallic impurities in the synthesis process.BackgroundFor radiopharmaceuticals the general requirements are listed in European Pharmacopeia and these parameters have to be checked before application for human use.Materials and methodsStandard methods for the determination of basic characteristics of radiopharmaceuticals were used. Additionally, high resolution γ spectrometry was used for the assessment of nuclidic purity and inductively coupled plasma with mass spectrometry to evaluate metallic content.ResultsResults showed sources and distribution of metallic and radiometallic impurities in the production process. Main part is trapped in the initial separation column of the synthesis unit and is not distributed to the final product in significant amounts.ConclusionsProduced ¹⁸FDG filled requirements of Ph.Eur. and the content of radionuclidic and metallic impurities was in the acceptable range.     

Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals

The aim of this study was to evaluate new ligands which can be applied for labeling biomolecules with scandium radionuclides. Two radionuclides of scandium, ⁴⁷Sc and ⁴⁴Sc, are perspective radioisotopes for radiotherapy and diagnostic imaging. ⁴⁷Sc decays with a half-life of 3.35 days and a maximum β⁻ energy of 600 keV and could be an alternative to carrier added ¹⁷⁷Lu radionuclide for targeted radionuclide therapy. Another scandium radionuclide ⁴⁴Sc (t_1/2 = 3.92 h) is an ideal β⁺ emitter for PET diagnosis. It can be obtained as a daughter of the long-lived ⁴⁴Ti (t_1/2 = 60.4 y) from ⁴⁴Ti/⁴⁴Sc generator. For complexation of scandium radionuclides macrocyclic ligands having a cavity size similar to Sc³⁺ ionic radius were selected: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7 triacetic acid (NOTA), 1,4,7-triazacyclodecane-1,4,7 triacetic acid and 1,4,7-triazacycloundecane triacetic acid, and analogs of NOTA with 10, 11 and 12 atoms of the carbon in the ring. Our results have shown that from the studied macrocyclic ligands studied DOTA is most efficient for binding scandium radionuclides ⁴⁴Sc and ⁴⁷Sc to biomolecules. The determined stability constant of Sc-DOTA complex logK = 27.0 is comparable with stability constants for Y³⁺ and heaviest lanthanides but is higher than those for In³⁺ and Ga³⁺. Also ⁴⁶Sc-DOTATATE conjugate exhibits high stability in-vitro studies. The ¹³C NMR studies have shown that Sc-DOTA like Lu-DOTA forms in solution complexes with eight-coordination geometry. The lipophilicity of Sc-DOTATATE is nearly identical to that of Lu-DOTATATE, which suggests similar receptor affinity of both radioconjugates.     

A new bisphosphonate-containing <Superscript>99m</Superscript>Tc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation

Aiming to develop new bone-seeking radiotracers based on the organometallic core fac-[^99mTc(CO)₃]⁺ with improved radiochemical and biological properties, we have prepared new conjugates with phosphonate pendant groups. The conjugates comprise a chelating unit for metal coordination, which corresponds to a pyrazolyl-containing backbone (pz) with a N,N,N donor-atom set, and a pendant diethyl phosphonate (pz-MPOEt), phosphonic acid (pz-MPOH) or a bisphosphonic acid (pz-BPOH) group for bone targeting. Reactions of the conjugates with the precursor [^99mTc(H₂O)₃(CO)₃]⁺ yielded (mote than 95%) the single and well-defined radioactive species [^99mTc(CO)₃(κ³-pz-MPOEt)]⁺ (1a), [^99mTc(CO)₃(κ³-pz-MPOH]⁺ (2a) and [^99mTc(CO)₃(κ³-pz-BPOH)]⁺ (3a), which were characterized by reversed-phase high-performance liquid chromatography . The corresponding Re surrogates (1–3), characterized by the usual analytical techniques, including X-ray diffraction analysis in the case of 1, allowed for macroscopic identification of the radioactive conjugates. These radioactive complexes revealed high stability both in vitro (phosphate-buffered saline solution and human plasma) and in vivo, without any measurable decomposition. Biodistribution studies of the complexes in mice indicated a fast rate of blood clearance and high rate of total radioactivity excretion, occurring primarily through the renal–urinary pathway in the case of complex 3a. Despite presenting moderate bone uptake (3.04 ± 0.47% injected dose per gram of organ, 4 h after injection), the high stability presented by 3a and its adequate in vivo pharmacokinetics encourages the search for new ligands with the same chelating unit and different bisphosphonic acid pendant arms.     

An automated method for regular productions of copper-64 for PET radiopharmaceuticals

To facilitate the development of PET radiopharmaceuticals labelled with the positron-emitting radioisotope copper-64 (t_1/2 = 12.7 h) we have developed a fully automated method for its regular productions. Using the ⁶⁴Ni(p,n)⁶⁴Cu nuclear reaction applied on a 16.5 MeV PETtrace cyclotron the radioisotope is generated in good yields (up to 2 GBq at end-of-synthesis) within 4 h irradiations on nickel-64 (99.6% enrichment) plated onto a gold disk. Based on ion exchange chromatography an automated method has been devised for efficient extraction of the copper-64 in good radionuclide and chemical purity, with ICP-OES analysis determining the concentration of the copper to be 0.14-1.5 ppm. The specific radioactivities of the copper-64 at end-of-synthesis were calculated to be 9.62-77 GB/μmol. The copper-64 radioisotope obtained from this method was then applied to the radiosynthesis of the hypoxia markers, ⁶⁴Cu-ATSM and ⁶⁴Cu-ATSE, which were obtained in good radiochemical yields of >95%.